Xunlianpin’s third Xiaojinji IPO, targeting cell therapy! The "Regenerative Medicine Act" is stuck, how to deal with it?
Posted: Wed Jan 08, 2025 4:08 am
Benefiting from the increasing development opportunities in the biotech medical industry, Xunlian Biotech, the first listed OTC company in China specializing in cell therapy, has revenue in the first half of this year (2023) reaching NT$553 million. increased by 17.26%, operating profit was 68 million yuan, after-tax earnings were 55 million yuan, and earnings per share were 1.16 yuan, an increase of 0.25 yuan compared with the same period last year.
Xunlian Biotechnology Chairman Cai Zhengxian pointed out the five keys to revenue growth at today's (9th) performance conference, namely: mesenchymal stem cell (MSC) clinical case revenue growth of 60%, exosomes (exosomes) The product and OEM performance increased by 201%, the performance of CDMO services increased by 225% in the first half indonesia telegram of the year, the special control law accelerated the accumulation of cases, and the genetic testing business through comprehensive non-invasive fetal chromosome testing (NIPT) bucked the trend and grew by 20%.
Cai Zhengxian, Chairman of Xunlian Biotech
Cai Zhengxian, chairman of Xunlian Biotech.
Picture/Lin Zhiyuan
Not affected by the bill's blockage, Xunlian continues to promote 60 cell therapy projects
Founded in 1999, Xunlian Biotechnology provides various cell, exosome, gene, testing, medical beauty and skin care products and other product technologies. So far, it has served more than 50% of newborns, 95.5% of reproductive medicine centers, and cooperated with more than 500 medical hospitals. institute and expanded to 17 overseas countries.
Stay on top of the latest AI, semiconductor, and digital trends! Subscribe to the "Digital Times" daily newspaper and social event information
Please enter Email
The so-called "cell therapy" means that an individual's own cells (autologous cells) or other individuals' cells (allogeneic cells) are introduced into the patient's body after in vitro culture or processing procedures to achieve the purpose of treating or preventing diseases. Common clinical application scenarios include umbilical cord blood, bone marrow transplantation, etc.
Xunlian Biotechnology Chairman Cai Zhengxian pointed out the five keys to revenue growth at today's (9th) performance conference, namely: mesenchymal stem cell (MSC) clinical case revenue growth of 60%, exosomes (exosomes) The product and OEM performance increased by 201%, the performance of CDMO services increased by 225% in the first half indonesia telegram of the year, the special control law accelerated the accumulation of cases, and the genetic testing business through comprehensive non-invasive fetal chromosome testing (NIPT) bucked the trend and grew by 20%.
Cai Zhengxian, Chairman of Xunlian Biotech
Cai Zhengxian, chairman of Xunlian Biotech.
Picture/Lin Zhiyuan
Not affected by the bill's blockage, Xunlian continues to promote 60 cell therapy projects
Founded in 1999, Xunlian Biotechnology provides various cell, exosome, gene, testing, medical beauty and skin care products and other product technologies. So far, it has served more than 50% of newborns, 95.5% of reproductive medicine centers, and cooperated with more than 500 medical hospitals. institute and expanded to 17 overseas countries.
Stay on top of the latest AI, semiconductor, and digital trends! Subscribe to the "Digital Times" daily newspaper and social event information
Please enter Email
The so-called "cell therapy" means that an individual's own cells (autologous cells) or other individuals' cells (allogeneic cells) are introduced into the patient's body after in vitro culture or processing procedures to achieve the purpose of treating or preventing diseases. Common clinical application scenarios include umbilical cord blood, bone marrow transplantation, etc.